[Assessment of early treatment results with antineoplaston AS2-1 in subacute sclerosing panencephalitis].
A tentative treatment with Antineoplaston AS2-1 was carried out in a group of 16 patients with subacute sclerosing panencephalitis (SSPE). Most patients were in phase II of SSPE (after Jabbour) with mean disease duration 6.4 months. Their age ranged from 13 to 28 years. They were given for 6 months 15 capsules of Antineoplaston AS2-1 and 6 tablets of isoprinosine daily. Despite that treatment progression was observed of the disturbances of higher nervous functions, less so of motor functions. The treatment had no effect on MRI results, EEG and antimeasles antibodies levels. No adverse effects were observed.
Sobczyk
W
W
I Kliniki Neurologicznej IPiN w Warszawie.
Piłkowska
E
E
Iwińska-Buksowicz
B
B
Jakubowska
T
T
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use; D008297:Male; D010648:Phenylacetates / Q000627:therapeutic use*; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004338:Drug Combinations; D010648:Phenylacetates; D005973:Glutamine; C092038:antineoplaston AS 2-1; D007542:Inosine Pranobex
Ocena bezpośrednich (wczesnych) wyników leczenia antyneoplastonem AS2-1 u chorych z podostrym stwardniajacym zapaleniem mózgu (SSPE).